Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014 May;35(5):4077-85.
doi: 10.1007/s13277-013-1533-1. Epub 2013 Dec 29.

Risk of severe diarrhea with dual anti-HER2 therapies: a meta-analysis

Hui Li  1 , Wenyan Fu, Xiang Gao, Qunfang Xu, Hua Wu, Wenlong Tan
Affiliations
Meta-Analysis

Risk of severe diarrhea with dual anti-HER2 therapies: a meta-analysis

Hui Li et al. Tumour Biol. 2014 May.

Abstract

Although promising progress has been made with dual HER2 blockade in patients with HER2-positive breast cancer, whether the strategy of combined HER2 blockade increases the risk of severe diarrhea remains inclusive. In the present study, we investigated the overall incidence and risk of severe diarrhea when patients were treated with a combination of anti-HER2 therapies compared to anti-HER2 monotherapy. Studies that evaluated the administration of an anti-HER2 monotherapy (lapatinib or trastuzumab or pertuzumab) versus anti-HER2 combination therapy (pertuzumab plus trastuzumab or trastuzumab plus lapatinib) in breast cancer were identified from the PubMed database (1966-2013), the Cochrane library, abstracts presented at the American Society of Clinical Oncology annual conference (2004-2013), and the Web of Science database (1998-2013). Eligible studies were those in which the only systematic difference between the study arms was the type of anti-HER2 therapy used. Incidence, relative risk (RR), and 95% confidence intervals (CIs) were calculated using random effects or fixed-effects models based on the heterogeneity of the included studies. Seven trials were considered eligible. The overall incidence results for severe diarrhea in the combined anti-HER2 therapy and the anti-HER2 monotherapy were 3.48% (95% CI: 11.60-15.37%) and 8.68% (9 % CI: 7.33-10.03%), respectively. The odds ratio (OR) of severe diarrhea between anti-HER2 combination therapy and monotherapy was 1.67 (95% CI: 1.38 -5.57, p = 0.00001). This meta-analysis provides evidence that the incidence rates of severe diarrhea are comparable between anti-HER2 combination therapy and anti-HER2 monotherapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. J Clin Oncol. 2012 Jul 20;30(21):2585-92 - PubMed
    1. Nat Clin Pract Oncol. 2006 May;3(5):269-80 - PubMed
    1. BMC Cancer. 2012 Jul 28;12:322 - PubMed
    1. Breast Cancer Res. 2006;8(6):215 - PubMed
    1. J Clin Oncol. 2012 Jun 1;30(16):1989-95 - PubMed

Publication types

LinkOut - more resources